Detection of Rifampicin- and Isoniazid-Resistant Mycobacterium tuberculosis Using the Quantamatrix Multiplexed Assay Platform System

Annals of Laboratory Medicine
Hye-Young WangH Lee

Abstract

The increasing prevalence of drug-resistant tuberculosis (TB) infection represents a global public health emergency. We evaluated the usefulness of a newly developed multiplexed, bead-based bioassay (Quantamatrix Multiplexed Assay Platform [QMAP], QuantaMatrix, Seoul, Korea) to rapidly identify the Mycobacterium tuberculosis complex (MTBC) and detect rifampicin (RIF) and isoniazid (INH) resistance-associated mutations. A total of 200 clinical isolates from respiratory samples were used. Phenotypic anti-TB drug susceptibility testing (DST) results were compared with those of the QMAP system, reverse blot hybridization (REBA) MTB-MDR assay, and gene sequencing analysis. Compared with the phenotypic DST results, the sensitivity and specificity of the QMAP system were 96.4% (106/110; 95% confidence interval [CI] 0.9072-0.9888) and 80.0% (72/90; 95% CI 0.7052-0.8705), respectively, for RIF resistance and 75.0% (108/144; 95% CI 0.6731-0.8139) and 96.4% (54/56; 95% CI 0.8718-0.9972), respectively, for INH resistance. The agreement rates between the QMAP system and REBA MTB-MDR assay for RIF and INH resistance detection were 97.6% (121/124; 95% CI 0.9282-0.9949) and 99.1% (109/110; 95% CI 0.9453-1.0000), respectively. Comparison betwee...Continue Reading

References

Jul 8, 2000·Microbes and Infection·R A Slayden, C E Barry
Jan 14, 2009·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Said H AbbadiR C Cooksey
Apr 24, 2010·Journal of Health, Population, and Nutrition·K Zaman
May 28, 2010·Journal of Clinical Microbiology·Robert BlakemoreDavid Alland
Jul 21, 2010·Indian Journal of Medical Microbiology·A HristeaA Streinu-Cercel
Apr 13, 2011·Clinical Microbiology Reviews·Linda M ParsonsJohn Nkengasong
Oct 20, 2011·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·G K SkendersV Leimane
Feb 14, 2012·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·J JinW Zhang
Apr 25, 2014·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·F RageadeA van Belkum
Jul 1, 2015·Chemical Communications : Chem Comm·Lily Nari KimSunghoon Kwon
Nov 29, 2015·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·M CausseM Casal
Apr 17, 2016·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·M SeifertT C Rodwell
Dec 22, 2016·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·H Y WangH Lee

❮ Previous
Next ❯

Methods Mentioned

BETA
nucleic acid amplification
PCR
reverse
Assay
fluorescence microscopy

Clinical Trials Mentioned

NCT00341601

Software Mentioned

QMAP
SPSS
GeneXpert
REBA
QuantaMatrix

Related Concepts

Related Feeds

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.